Cost-Effectiveness of SAPIEN 3 Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in German Severe Aortic Stenosis Patients at Low Surgical Mortality Risk.
Aortic stenosis
Cost-effectiveness
Cost–utility analysis
Low risk
Surgical aortic valve replacement
Tanscatheter aortic valve implantation (TAVI)
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
17
10
2022
accepted:
28
11
2022
pubmed:
10
1
2023
medline:
9
3
2023
entrez:
9
1
2023
Statut:
ppublish
Résumé
In the randomized PARTNER 3 trial, transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 device significantly reduced a composite of all-cause death, stroke, and rehospitalization, compared with surgical aortic valve replacement (SAVR), in patients with severe symptomatic aortic stenosis and low risk of surgical mortality. Furthermore, TAVI has been shown to be cost-effective in low-risk patients, compared with SAVR, in a number of countries. This study aimed to determine the cost-effectiveness of TAVI with SAPIEN 3 versus SAVR in Germany. A previously published two-stage Markov-based model that captured clinical outcomes from the PARTNER 3 trial was adapted for the German context using the German Statutory Health Insurance perspective. The model had a lifetime horizon. The cost-utility analysis estimated changes in direct healthcare costs as well as survival and health-related quality of life using TAVI with SAPIEN 3 compared with SAVR. TAVI with SAPIEN 3 increased quality-adjusted life years (QALYs) by + 0.72 at an increased cost of €8664 per patient. The incremental cost-effectiveness/QALY ratio was €12,037, which fell below that of other cardiovascular interventions in use in Germany. The cost-effectiveness of TAVI over SAVR remained robust across multiple challenging scenarios and was driven by lower longer-term management costs compared with SAVR. TAVI with SAPIEN 3 appears to be a clinically meaningful, cost-effective treatment option over SAVR for patients with severe symptomatic aortic stenosis and low risk for surgical mortality in Germany. www. gov identifier: NCT02675114.
Identifiants
pubmed: 36622552
doi: 10.1007/s12325-022-02392-y
pii: 10.1007/s12325-022-02392-y
pmc: PMC9988804
doi:
Banques de données
ClinicalTrials.gov
['NCT02675114']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1031-1046Informations de copyright
© 2023. The Author(s).
Références
Boskovski MT, Gleason TG. Current therapeutic options in aortic stenosis. Circ Res. 2021;128(9):1398–417.
doi: 10.1161/CIRCRESAHA.121.318040
pubmed: 33914604
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2021;60(4):727–800.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. New Engl J Med. 2019;380(18):1695–705.
doi: 10.1056/NEJMoa1814052
pubmed: 30883058
Kuck K-H, Bleiziffer S, Eggebrecht H, et al. Consensus paper of the German Society of Cardiology (DGK) and the German Society of Thoracic, Cardiovascular and Vascular Surgery (DGTHG) on catheter-assisted aortic valve implantation (TAVI) 2020. Kardiologie. 2020;14:182–204.
doi: 10.1007/s12181-020-00398-w
Ali N, Faour A, Rawlins J, et al. ‘Valve for life’: tackling the deficit in transcatheter treatment of heart valve disease in the UK. Open Heart. 2021;8(1):001547.
doi: 10.1136/openhrt-2020-001547
Kim WK, Hamm CW. Transcatheter aortic valve implantation in Germany. Clinical Res Cardiol. 2018;107(2):81–7.
doi: 10.1007/s00392-018-1297-0
Gilard M, Eltchaninoff H, Iung B, et al. Cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation procedure compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in France. Value Health. 2022;25(4):605–13.
doi: 10.1016/j.jval.2021.10.003
pubmed: 35365304
Mennini FS, Meucci F, Pesarini G, et al. Cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in low surgical risk aortic stenosis patients. Int J Cardiol. 2022;357:26–32.
doi: 10.1016/j.ijcard.2022.03.034
pubmed: 35306028
Vázquez Rodríguez J, Pinar Bermúdez E, Zamorano Gómez J, et al. Cost-effectiveness of SAPIEN 3 transcatheter aortic valve implantation in low surgical mortality risk patients in Spain. REC Interv Cardiol. 2022. https://doi.org/10.24875/RECICE.M22000340 .
IQWiG. General Methods. Version 6.1 of 24 January 2022. https://www.iqwig.de/methoden/general-methods_version-6-1.pdf . Accessed Nov 23, 2022.
Tamm AR, Hell MM, Geyer M, et al. Minimizing paravalvular regurgitation with the novel SAPIEN 3 ultra TAVR prosthesis: a real-world comparison study. Front Cardiovasc Med. 2021;8: 623146.
doi: 10.3389/fcvm.2021.623146
pubmed: 33816574
pmcid: 8015438
Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77(9):1149–61.
doi: 10.1016/j.jacc.2020.12.052
pubmed: 33663731
Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, et al. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg. 2015;99(3):831–7.
doi: 10.1016/j.athoracsur.2014.09.030
pubmed: 25583467
Makkar RR, Thourani VH, Mack MJ, et al. Five-year outcomes of transcatheter or surgical aortic-valve replacement. New Eng J Med. 2020;382(9):799–809.
doi: 10.1056/NEJMoa1910555
pubmed: 31995682
Fujita B, Schmidt T, Bleiziffer S, et al. Impact of new pacemaker implantation following surgical and transcatheter aortic valve replacement on 1-year outcome. Eur J Cardiothorac Surg. 2020;57(1):151–9.
doi: 10.1093/ejcts/ezz168
pubmed: 31199470
Mensch A, Stock S, Stollenwerk B, Müller D. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics. 2015;33(3):271–83.
doi: 10.1007/s40273-014-0236-9
pubmed: 25404426
Gandjour A, Stock S. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy. 2007;83(2–3):257–67.
doi: 10.1016/j.healthpol.2007.01.003
pubmed: 17335933
Walter E, Voit M, Eichhober G. Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients. Expert Rev Pharmacoecon Outcomes Res. 2021;21(2):265–75.
doi: 10.1080/14737167.2020.1798233
pubmed: 32700584
Ali M, MacIsaac R, Quinn TJ, et al. Dependency and health utilities in stroke: data to inform cost-effectiveness analyses. Eur Stroke J. 2017;2(1):70–6.
doi: 10.1177/2396987316683780
pubmed: 30009266
pmcid: 6027777
Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. Dordrecht (NL): Springer; 2014.
Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the EQ-5D-5L. PharmacoEconomics. 2018;36(6):663–74.
Leidl R, Reitmeir P. An experience-based value set for the EQ-5D-5L in Germany. Value Health. 2017;20(8):1150–6.
doi: 10.1016/j.jval.2017.04.019
pubmed: 28964448
Butter C, Groß J, Haase-Fielitz A, et al. Impact of rehabilitation on outcomes after TAVI: a preliminary study. J Clin Med. 2018;7(10):326.
doi: 10.3390/jcm7100326
pubmed: 30301135
pmcid: 6210128
Eichler S, Völler H, Reibis R, et al. Geriatric or cardiac rehabilitation? Predictors of treatment pathways in advanced age patients after transcatheter aortic valve implantation. BMC Cardiovasc Disord. 2020;20(1):158.
doi: 10.1186/s12872-020-01452-x
pubmed: 32252646
pmcid: 7137198
Borisenko O, Müller-Ehmsen J, Lindenfeld J, Rafflenbeul E, Hamm C. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany. BMC Cardiovasc Disord. 2018;18(1):163.
doi: 10.1186/s12872-018-0898-x
pubmed: 30092774
pmcid: 6085633
Hadwiger M, Frielitz FS, Eisemann N, et al. Cardiac resynchronisation therapy in patients with moderate to severe heart failure in Germany: a cost-utility analysis of the additional defibrillator. Appl Health Econ Health Policy. 2021;19(1):57–68.
doi: 10.1007/s40258-020-00571-y
pubmed: 32215877
Aronsson M, Walfridsson H, Janzon M, et al. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. Europace. 2015;17(1):48–55.
doi: 10.1093/europace/euu188
pubmed: 25341739
Zhou JY, Liew D, Duffy SJ, Walton A, Htun N, Stub D. Cost-effectiveness of transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis. Heart Lung Circ. 2021;30(4):547–54.
doi: 10.1016/j.hlc.2020.09.934
pubmed: 33189571
Tam DY, Azizi PM, Fremes SE, Chikwe J, Gaudino M, Wijeysundera HC. The cost-effectiveness of transcatheter aortic valve replacement in low surgical risk patients with severe aortic stenosis. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):556–63.
doi: 10.1093/ehjqcco/qcaa058
pubmed: 32645146
HAS-Sante. SAPIEN 3 treatment of severe symptomatic aortic stenosis in low-risk surgical patients in France. 2021. https://www.has-sante.fr/upload/docs/application/pdf/2021-04/sapien3_9022021_avis_economique_vf2.pdf . Accessed Nov 23, 2022.
NIPH (Norwegian Institute of Public Health). Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups: a health technology assessment. 2021. https://www.fhi.no/en/publ/2021/TAVI-vs-SAVR-for-patients-with-severe-aortic-stenosis-and-low-surgical-risk-and-across-surgical-risk-groups/ . Accessed Nov 23, 2022.
Geisler BP, Jørgensen TH, Thyregod HGH, Pietzsch JB, Søndergaard L. Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients at lower surgical risk: results from the NOTION trial. EuroIntervention. 2019;15(11):e959–67.
doi: 10.4244/EIJ-D-18-00847
pubmed: 31422922
HIQA (Health Information and Quality Authority). Health Technology Assessment of transcatheter aortic valve implantation (TAVI) in patients with severe symptomatic aortic stenosis at low and intermediate risk of surgical complications. 2019. https://www.hiqa.ie/sites/default/files/2019-12/TAVI_HTA.pdf . Accessed Nov 23, 2022.
G-DRG. Estimated 2021 revenue values for G-DRG F98B and F03E. 2021. https://www.g-drg.de/Datenbrowser_und_Begleitforschung/G-DRG-Report-Browser/aG-DRG-Report-Browser_2021 . Accessed Nov 23, 2022.
Karoff M, Held K, Bjarnason-Wehrens B. Cardiac rehabilitation in Germany. Eur J Cardiovasc Prev Rehabil. 2007;14(1):18–27.
doi: 10.1097/HJR.0b013e3280128bde
pubmed: 17301623
Reinhold T, Lindig C, Willich SN, Brüggenjürgen B. The costs of atrial fibrillation in patients with cardiovascular comorbidities—a longitudinal analysis of German health insurance data. Europace. 2011;13(9):1275–80.
doi: 10.1093/europace/eur116
pubmed: 21515590
Albrecht D, Wollensak T, Ernst C, Becker C, Hautzinger M, Pfeiffer K. Costs of informal care in a sample of German geriatric stroke survivors. Eur J Ageing. 2016;13(1):49–61.
doi: 10.1007/s10433-015-0356-x
pubmed: 28804371
Kaier K, von Kampen F, Baumbach H, et al. Two-year post-discharge costs of care among patients treated with transcatheter or surgical aortic valve replacement in Germany. BMC Health Serv Res. 2017;17(1):473.
doi: 10.1186/s12913-017-2432-8
pubmed: 28693565
pmcid: 5504607
Gutmann A, Kaier K, Sorg S, et al. Analysis of the additional costs of clinical complications in patients undergoing transcatheter aortic valve replacement in the German Health Care System. Int J Cardiol. 2015;179:231–7.
doi: 10.1016/j.ijcard.2014.11.095
pubmed: 25464455
G-DRG. Estimated revenue values for DRG F62B. 2021. https://www.g-drg.de/Datenbrowser_und_Begleitforschung/G-DRG-Report-Browser/aG-DRG-Report-Browser_2021 . Accessed Nov 23, 2022.